Internal Medicine, Pulmonary Disease · Williamsville, NY
NPI
1184608911
Since 2005
Specialty
Internal Medicine, Pulmonary Disease
Code 207RP1001X
Group practices
2
Medicare group memberships
Hospitals
1
Hospital affiliations
6460 Main St, Buffalo Cardiology & Pulmonary Assoc PC
Williamsville, NY, 14221
Phone (716) 634-5100
Groups this clinician bills Medicare through
Medicare paid, 2024
$52K
894 services
Medicare patients, 2024
403
Average age 72
Drug cost, 2024
$2.7M
6,433 prescriptions
Company payments, 2025
$3,423
From 21 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Jeffery R Neu was code 99214 (office e&m - established), 321 times for 222 patients. In total Jeffery R Neu billed 894 services in 16 codes, and Medicare paid $52K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2010-02-12.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99214 Office E&M - Established | Office | 321 | 222 | $85.00 | $27K |
| 94727 Pulmonary Function Testing | Office | 93 | 93 | $31.92 | $2,968 |
| 94729 Pulmonary Function Testing | Office | 93 | 93 | $41.20 | $3,832 |
| J7620 Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | Office | 88 | 88 | $0.15 | $12.77 |
| 94060 Pulmonary Function Testing | Office | 86 | 86 | $26.82 | $2,306 |
| 99213 Office E&M - Established | Office | 72 | 69 | $55.77 | $4,016 |
| 99204 Office E&M - New | Office | 71 | 71 | $115.49 | $8,200 |
| 94010 Pulmonary Function Testing | Office | 45 | 38 | $20.22 | $910 |
By year: 2022 $74K for 1,187 services; 2023 $75K for 1,222 services; 2024 $52K for 894 services.
Medicare prescription drug claims, 2024
In 2024, the drug Jeffery R Neu prescribed most often to Medicare patients was Prednisone, with 1,550 prescriptions and refills. In total Jeffery R Neu wrote 6,433 Medicare prescriptions that cost $2.7M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Prednisone Generic | 1,550 | 1,686 | 414 | $7,271 |
| Albuterol Sulfate Hfa Albuterol Sulfate | 987 | 1,087 | 317 | $31K |
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 905 | 1,148 | 176 | $721K |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 390 | 494 | 88 | $70K |
| Symbicort Budesonide/Formoterol Fumarate | 203 | 269 | 55 | $61K |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 176 | 212 | 44 | $130K |
| Alprazolam Generic | 147 | 147 | 25 | $589 |
| Doxycycline Monohydrate Generic | 135 | 135 | 96 | $963 |
| Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate | 120 | 146 | 46 | $27K |
| Montelukast Sodium Generic | 115 | 193 | 22 | $1,090 |
| Breo Ellipta Fluticasone/Vilanterol | 112 | 124 | 21 | $48K |
| Zolpidem Tartrate Generic | 98 | 98 | 15 | $731 |
| Fluticasone Propionate Generic | 98 | 126 | 30 | $1,218 |
| Anoro Ellipta Umeclidinium Brm/Vilanterol Tr | 93 | 118 | 18 | $53K |
| Combivent Respimat Ipratropium/Albuterol Sulfate | 80 | 136 | 20 | $69K |
Brand drugs: - claims; generic drugs: 3,791 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Jeffery R Neu $3,423 ($3,423 in general payments such as food, travel and fees) from 21 companies. The largest payer was GlaxoSmithKline, LLC. with $523.
| Company | Payments | Amount |
|---|---|---|
| GlaxoSmithKline, LLC. GSK | 40 | $523 |
| AstraZeneca Pharmaceuticals LP AZN | 20 | $409 |
| Grifols USA, LLC | 12 | $281 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 6 | $250 |
| Regeneron Healthcare Solutions, Inc. REGN | 10 | $233 |
| Verona Pharma, Inc. VRNA | 8 | $212 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 9 | $203 |
| Insmed, Inc. INSM | 18 | $193 |
| Mallinckrodt Hospital Products Inc. | 5 | $177 |
| Viatris Specialty LLC | 8 | $176 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.